Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

José M. Pimiento

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7237-4509; OpenAlex author ID A5091641523. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 3 papers · 2016: 4 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 4 papers

Papers 22

  1. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-025-01277-9↗
  2. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-25-0237↗
  3. Lifetime stressor exposure and depression among patients with pancreatic cancer: insights from the Florida Pancreas Collaborative. Co-author DOI 10.1186/s12885-025-15007-w↗
  4. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17111797↗
  5. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of t… Co-author DOI 10.3389/fonc.2024.1362244↗
  6. The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization. Co-author DOI 10.1016/j.sopen.2023.02.001↗
  7. Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Co-author DOI 10.1007/s00464-021-08845-9↗
  8. Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study. Co-author DOI 10.1097/as9.0000000000000197↗
  9. The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis. Co-author DOI 10.1097/sla.0000000000003706↗
  10. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  11. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. Co-author DOI 10.1002/jso.26103↗
  12. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pa… Co-author DOI 10.1186/s12885-020-07182-9↗
  13. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. Co-author DOI 10.21037/jgo.2017.09.13↗
  14. TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.13533↗
  15. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal… Co-author DOI 10.1016/j.surg.2016.04.039↗
  16. Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000580↗
  17. Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer. Co-author DOI 10.1097/rlu.0000000000001098↗
  18. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-015-5006-1↗
  19. Annexin A8 Is a Prognostic Marker and Potential Therapeutic Target for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000218↗
  20. Robotic Whipple Procedure for Pancreatic Cancer: The Moffitt Cancer Center Pathway. Co-author DOI 10.1177/107327481502200313↗
  21. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0133562↗
  22. Vitamin E δ-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. Co-author DOI 10.1371/journal.pone.0052526↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mokenge Peter Malafa · 19 shared papers, 2013–2025 · strength 1.92
  2. Pamela Joy Hodul · 13 shared papers, 2013–2025 · strength 1.52
  3. Jason B. Fleming · 9 shared papers, 2020–2025 · strength 1.27
  4. Jennifer B. Permuth · 6 shared papers, 2021–2025 · strength 0.91
  5. Jason W. Denbo · 5 shared papers, 2020–2025 · strength 0.75
  6. Dung‐Tsa Chen · 8 shared papers, 2013–2025 · strength 0.63
  7. Benjamin Daniel Powers · 5 shared papers, 2020–2023 · strength 0.62
  8. Daniel A. Anaya · 4 shared papers, 2021–2023 · strength 0.56
  9. Daniel K. Jeong · 3 shared papers, 2025 · strength 0.50
  10. Vic Velanovich · 3 shared papers, 2025 · strength 0.50
  11. Margaret A. Park · 3 shared papers, 2025 · strength 0.50
  12. Dae Won Kim · 3 shared papers, 2022–2025 · strength 0.50
  13. Joon Kyung Kim · 3 shared papers, 2020–2023 · strength 0.38
  14. Kun Jiang · 2 shared papers, 2025 · strength 0.35
  15. Dae Won Kim · 2 shared papers, 2022–2025 · strength 0.33
  16. Sarah E. Hoffe · 3 shared papers, 2016–2025 · strength 0.33
  17. Sarah M. Judge · 2 shared papers, 2025 · strength 0.31
  18. Nathan H. Parker · 2 shared papers, 2025 · strength 0.31
  19. Andrew R. Judge · 2 shared papers, 2025 · strength 0.31
  20. Evan W. Davis · 2 shared papers, 2025 · strength 0.31
  21. Paul A. Stewart · 2 shared papers, 2025 · strength 0.31
  22. J. Pablo Arnoletti · 2 shared papers, 2025 · strength 0.31
  23. Jose Gilberto Trevino · 2 shared papers, 2025 · strength 0.31
  24. Sylvia L. Crowder · 2 shared papers, 2025 · strength 0.31
  25. Ghulam Rasool · 2 shared papers, 2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.